Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study

Background/Aims Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). However, its efficacy, safety, and the appropriate dosage have not been extensively investigated in the Japanese pop...

Полное описание

Библиографические подробности

Главные авторы:	Ken Takeuchi, Hiroshi Nakase, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Shoko Arai, Hirotoshi Yuasa, Motoki Oe, Ryosuke Ono, Michael Keating, Guibao Gu, Krisztina Lazin, Aoibhinn McDonnell, Koki Fukuta, Toshifumi Hibi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Korean Association for the Study of Intestinal Diseases 2026-04-01
Серии:	Intestinal Research
Предметы:	s1p receptor modulator etrasimod ulcerative colitis
Online-ссылка:	http://irjournal.org/upload/pdf/ir-2024-00213.pdf
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!